Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZMIZ1 antisense RNA 1 (ZMIZ1-AS1) is a long noncoding RNA (lncRNA) transcribed from the antisense strand of the ZMIZ1 gene locus. As an antisense lncRNA, ZMIZ1-AS1 is believed to regulate the expression of its sense counterpart ZMIZ1 or other genes through mechanisms common to lncRNAs, such as RNA-RNA base pairing, chromatin modification, or acting as a molecular scaffold. Elevated or altered expression of ZMIZ1-AS1 has been implicated in several malignancies, where it may act to promote tumor cell proliferation, invasion, or metastasis via regulation of oncogenic targets. However, ZMIZ1-AS1 itself is not a receptor, enzyme, transporter, or classical therapeutic target; its relevance is primarily as a noncoding RNA regulator and potential biomarker in cancer and possibly other diseases. No FDA- or clinically-approved drugs are known to target ZMIZ1-AS1 directly.
None established
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZMIZ1 antisense RNA 1 (ZMIZ1-AS1).